Animal Models Poorly Predict Human Drug Toxicity and Efficacy

More than 90% of drugs that work in animals fail in human trials. Mouse models of cancer, Alzheimer's, and inflammation are notoriously poor predictors. This is the fundamental reason clinical trials fail at such high rates and cost billions.

Species differences in drug metabolism (CYP450 isoforms), immune responses, and disease pathophysiology create a translation gap. The concordance between animal toxicology studies and human adverse events is estimated at 50-70% for rodents and 60-80% for non-human primates. Organ-on-chip technology (Emulate, Hesperos) and patient-derived organoids offer alternatives but are not yet validated as regulatory substitutes. The FDA Modernization Act 2.0 (2022) removed the requirement for animal testing before human trials, opening the door for alternative methods.

Why It Matters

50% of Phase II failures are due to lack of efficacy — the drug worked in animals but not humans. Unnecessary animal testing costs billions and delays drug development. Better predictive models could cut Phase II failure rates from 65% to potentially 30-40%.

Startup Approach

Develop human-relevant disease models (patient-derived organoids, organ-on-chip systems, or computational models) that better predict human drug response. Sell as a CRO service to pharma companies to de-risk their clinical programs before Phase II.

NIH Funding

NCATS Tissue Chip program funds organ-on-chip development. FDA Modernization Act 2.0 supports alternative testing methods. NIH Common Fund supports microphysiological systems research.

Who's Working On It

Emulate (organ-on-chip), Hesperos (human-on-chip), NCATS (tissue chip program), Recursion Pharmaceuticals (AI + phenotypic screening), Valo Health